Skip to content

Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03380299
Enrollment
2
Registered
2017-12-21
Start date
2016-07-14
Completion date
2018-12-14
Last updated
2017-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cellular Diagnosis, Chronic Lymphocytic Leukemia

Brief summary

The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation

Detailed description

Chronic lymphocytic leukemia (CLL) is the most common type of chronic leukemia, accounting for approximately 40% of all leukemia's and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL . The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation . CD49d (one of biomarkers) is one of independent prognostic risk parameter in CLL with important roles in shaping these interactions. CD49d also is one of independent prognostic risk parameters in CLL that predict adverse outcome and linked to processes involved in interaction with the vascular endothelium and/or migration into the extravascular compartments . The cell-surface glycoprotein CD44 is involved in cell motility, cellular trafficking, and stem cell differentiation . It contributes to the phenotypic hallmarks of many cancers, such as invasiveness, self-renewal, and sustained survival. CD44 transmits both growth and apoptotic signals, a functional duality that is also observed in hematologic malignancies. CD44 expression in CLL is mediated by the tumor microenvironment. As a coreceptor, CD44 promotes leukemogenesis by regulating stimuli of MCL1 expression. Moreover, CD44 can be addressed therapeutically in CLL by specific antibodies.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL

Inclusion criteria

* All patients are newly diagnosed as CLL

Exclusion criteria

* : patients with associated malignancies

Design outcomes

Primary

MeasureTime frameDescription
To what extent the identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .1 YEARdetecting membrane expression of CD49d and CD 44 and thier role in prognosis of CLL patients.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026